logo/base Created with Sketch.
Contact us

FibroScan® Compact 530

The portable non-invasive solution for efficient liver disease management.

Powered by LSM by VCTE® and CAP for liver disease assessment.

chevron chevron

From cart-based to transportable

FibroScan® Compact 530 is a point-of-care solution for private practice or office-based settings.

Portable

Easy to handle and transport. Battery-powered device provided with transport case

Adaptable

Optional roll stand with a lockable drawer for probes, and a keyboard

All Patient Morphologies

Can be used with all probes S+, M+ and XL+

Renowned & Endorsement

Supported by 6,270+ peer reviewed publications and 250+ international guidelines

Patented and Validated

LSM by VCTE® is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness with 5,540+ international peer-reviewed publications.1

CAP is unique patented and validated for liver steatosis assessment2,3 with 2,125+ international peer-reviewed publications.

Learn more
FibroScan® Compact 530

Guided VCTE®: the next generation VCTE® technology

The new Guided VCTE® technology offers intuitive features for faster examinations and simplified scanning.

Learn more about Guided VCTE More information about FibroScan exams

FibroScan® Compact 530 comes with a dedicated support

From installation, to training and local support, we provide you with the highest quality of services.

Learn more

Extend FibroScan® use

Beyond FibroScan®, Echosens offers complementary solutions designed to extend liver disease assessment, support clinical decision-making and optimize patient follow-up across different care pathways.

  • FibroScan® Guided VCTE

    Guided VCTE®

    Seamless liver health assessment for all

    chevron
  • FibroScan® probes

    VCTE® probe

    Optimize measurement accuracy on all patients of varying size

    chevron
  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron
  • FibroScan® Gateway

    FibroScan® Gateway

    Optimize clinical workflows with real-time secure data transmission

    chevron

What our users say

As a clinical researcher, I rely heavily on FibroScan to select the right patient for the right study. Clinical trials in non-alcoholic steatohepatitis typically include patients with specific fibrosis stages. It is thus important to have reliable fibrosis assessment and avoid unnecessary liver biopsies.

Vincent Wong

Hepatologist from Hong Kong

The ability FibroScan gives to painlessly and quickly locate a liver health risk to a person, which also is one of the world’s biggest silent killers is a no brainer. I have yet to have any person tell me they didn’t want to know, in fact the complete opposite almost everyone alters something in their lives to improve their own and families liver health. 

Louise Campbell

Founder and Medical Director Tawazun Health

Guided VCTE technology has significantly improved the operator’s confidence that the probe is in the right place over the liver, excluding either lung or rib artifact. This will also enhance reliability when performing sequential scans on the same patient.

Dr. Martin Grajower

MD, FACP, FACE | Endocrinologist, Clinical Professor of Medicine | Albert Einstein College of Medicine

Read all testimonials chevron

Request a demo!

Interested in FibroScan®?

Contact us

1.European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
2.Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.
3.Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d. 

The FibroScan® Compact 530 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE®) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP)* at 3.5 MHz. FibroScan liver stiffness measurements (LSM) by VCTE® may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid to clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided. *CAP refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP on S+ probe is only available with SmartExam capability.

chevron User Guides FibroScan Compact 530